Glenmark’s US partner receives marketing approval for Crofelemer 125mg tablets

02 Jan 2013 Evaluate

Glenmark Pharmaceuticals - partner in US - Salix Pharmaceuticals, has received marketing approval from US Food and Drug Administration (USFDA) for Crofelemer 125 mg delayed-release tablets for the symptomatic relief of non-infectious diarrhea in patients with human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy (ART).

Crofelemer is believed to improve HIV associated diarrhea via dual mechanisms of action with inhibition of both CFTR (Cystic Fibrosis Transmembrane Conductance Regulator Protein) and CaCC (calcium-activated chloride channel) resulting in reduced chloride ion secretion into the GI lumen.

Besides, the USFDA approval of Crofelemer for HIV associated diarrhea will pave the wave to launch Crofelemer across our territories. This is a significant approval milestone and will enable the first NCE launch by Glenmark across emerging markets.

Glenmark Pharma Share Price

1591.30 -35.25 (-2.17%)
09-Jan-2025 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1827.55
Dr. Reddys Lab 1368.95
Cipla 1490.40
Lupin 2252.45
Zydus Lifesciences 1010.15
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.